Comparison of Blood-Brain Barrier Models for in vitro Biological Analysis: One Cell Type vs Three Cell Types.

Different types of in vitro blood-brain barrier (BBB) models have been constructed and applied for drug transport to evaluate the efficacy of nano-carrier based drug delivery. However, the effectiveness of different types of BBB models has not been reported. In this paper, we developed two types of in vitro models: one-cell type BBB model developed using only endothelial cells and three-cell type BBB model obtained by co-culturing endothelial, pericyte and astrocyte cells. The nanoparticle transport mechanisms through BBB and transport efficiencies of the Lactoferrin attached silica nanoparticles were studied using both types of the in vitro BBB models. Compared with one-cell type model, the PSi-Lf NPs exhibit relatively lower transport efficiency across three-cell type BBB system. Moreover, the effects of the nanoparticle size on the transport efficacies are consistent for both models. For both types of BBB models, the transport efficacies of the NPs are size dependent, and the highest efficacies are achieved for NPs with 25 nm in diameter. Our experimental results indicate that the one-cell type and three-cell type BBB models are equivalent for evaluating and optimizing nanoparticle transport across BBB.

[1]  Yang Song,et al.  In Vitro Study of Receptor-Mediated Silica Nanoparticles Delivery across Blood-Brain Barrier. , 2017, ACS applied materials & interfaces.

[2]  J. Berwick,et al.  LRP-1-mediated intracellular antibody delivery to the Central Nervous System , 2015, Scientific Reports.

[3]  Krunal K. Mehta,et al.  Biomineralized anisotropic gold microplate-macrophage interactions reveal frustrated phagocytosis-like phenomenon: a novel paclitaxel drug delivery vehicle. , 2014, ACS applied materials & interfaces.

[4]  K. Dawson,et al.  Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. , 2014, ACS nano.

[5]  Yoshinobu Manome,et al.  Cell-Based in Vitro Blood–Brain Barrier Model Can Rapidly Evaluate Nanoparticles’ Brain Permeability in Association with Particle Size and Surface Modification , 2014, International journal of molecular sciences.

[6]  Peter C. Searson,et al.  The blood-brain barrier: an engineering perspective , 2013, Front. Neuroeng..

[7]  Dong Yun Lee,et al.  In vivo biodistribution and toxicology of carboxylated graphene quantum dots. , 2013, ACS nano.

[8]  Luca Cucullo,et al.  In vitro blood-brain barrier models: current and perspective technologies. , 2012, Journal of pharmaceutical sciences.

[9]  D. Emerich,et al.  Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. , 2010, Biochimica et biophysica acta.

[10]  Rongqin Huang,et al.  Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo , 2010, Brain Research Bulletin.

[11]  Joanna M. Wardlaw,et al.  Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis , 2009, Neurobiology of Aging.

[12]  Wei Lu,et al.  Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Chen Jiang,et al.  The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. , 2008, Biomaterials.

[14]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[15]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[16]  G. Savettieri,et al.  Permeability properties of a three‐cell type in vitro model of blood‐brain barrier , 2005, Journal of cellular and molecular medicine.

[17]  K. Hayashi,et al.  Effects of hypoxia on endothelial/pericytic co-culture model of the blood–brain barrier , 2004, Regulatory Peptides.

[18]  D. Begley Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[19]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[20]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[21]  E. Ezan,et al.  A co-culture-based model of human blood–brain barrier: application to active transport of indinavir and in vivo–in vitro correlation , 2002, Brain Research.

[22]  C. Lohmann,et al.  Predicting Blood-Brain Barrier Permeability of Drugs: Evaluation of Different In Vitro Assays , 2002, Journal of drug targeting.

[23]  J. Neumaier,et al.  A new model of the blood--brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions. , 1999, Neuroreport.

[24]  L. Rubin,et al.  A cell culture model of the blood-brain barrier , 1991, The Journal of cell biology.